Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Thrombomodulin alfa - Asahi Kasei Pharma

Drug Profile

Thrombomodulin alfa - Asahi Kasei Pharma

Alternative Names: ART-123; AT 908; Human recombinant thrombomodulin - Asahi Kasei Pharma; Recombinant human soluble thrombomodulin - Asahi Kasei Pharma; Recombinant thrombomodulin alfa - Asahi Kasei Pharma; Recombinant thrombomodulin alpha - Asahi Kasei Pharma; Recomodulin; Recomodulin® anticoagulant intravenous infusion 12800; rhs-TM - Asahi Kasei Pharma; Thrombomodulin alpha - Asahi Kasei Pharma; TMD-123

Latest Information Update: 29 Jan 2019

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Asahi Kasei; Asahi Kasei Pharma Corp
  • Developer Asahi Kasei; Asahi Kasei Pharma America Corp; Asahi Kasei Pharma Corp
  • Class Anti-inflammatories; Anticoagulants; Antithrombotics; Peptides; Platelet membrane glycoproteins; Recombinant proteins
  • Mechanism of Action Protein C stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Disseminated intravascular coagulation
  • Phase III Idiopathic pulmonary fibrosis
  • No development reported Deep vein thrombosis

Most Recent Events

  • 31 Dec 2018 Asahi Kasei Pharma Corporation completes a phase III trial in Idiopathic pulmonary fibrosis in Japan (NCT02739165)
  • 19 Oct 2018 Efficacy and adverse events data from a phase II trial in prevention of treatment-related symptoms in Colon cancer presented at the 43rd European Society for Medical Oncology Congress (ESMO-2018)
  • 02 Aug 2018 Preliminary efficacy and pharmacodynamics data from the phase III SCARLET trial in Disseminated intravascular coagulation released by Asahi Kasei Pharma America Corp
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top